Alchemab, Lilly partner on antibody-based treatments for ALS

Alchemab, Lilly partner on antibody-based treatments for ALS

Alchemab Therapeutics has partnered with Eli Lilly to develop new antibody treatments for amyotrophic lateral sclerosis (ALS) based on an approach that looks at the immune response of those with slower disease progression. Alchemab will identify, develop, and market up to five new antibody-based candidates. The company…

Revisiting the past is bittersweet when living with ALS

As we head into the new year, I’ve been in decluttering mode. I sorted through my linen closet and discarded worn sheets and pillowcases. I sorted through files and found old tax returns, bank statements, and receipts, and I burned sensitive papers in my mom’s sauna stove. And then I…

Dosing begins in Phase 1 trial of potential ALS therapy RAG-17

A Phase 1 clinical trial testing RAG-17, an investigational therapy for people with amyotrophic lateral sclerosis (ALS) carrying mutations in the SOD1 gene, has dosed its first participant. The trial (NCT06556394) aims to determine the safety and tolerability, pharmacological properties, and preliminary signs of efficacy of multiple dose levels of…